Medtronic PLC Form 4 insider transactions

Medtronic plc's EVP and President of Cardiovascular, Harry Skip Kiil, executed pre-planned transactions, exercising stock options and selling ordinary shares.

Medtronic's Chief Accounting Officer, Denise L. Blomquist, reported gifting 340 ordinary shares of the company.

Medtronic's Chief Accounting Officer, Denise L. Blomquist, disposed of 148 ordinary shares to cover tax liabilities related to vested restricted stock units.

Medtronic EVP Brett A. Wall reported the withholding of 439 ordinary shares for tax purposes related to restricted stock unit vesting.

Medtronic EVP Michael Marinaro disposed of 1,371 ordinary shares to cover tax liabilities related to restricted stock unit vesting.

Medtronic plc's Chairman and CEO, Geoffrey Martha, reported a disposition of 1,564 ordinary shares for tax purposes related to restricted stock unit vesting.

Medtronic plc's EVP and President of Cardiovascular, Harry Skip Kiil, reported the withholding of 1,702 ordinary shares for tax purposes related to restricted stock unit vesting.

Medtronic plc's Chief Accounting Officer, Denise L. Blomquist, reported the gift of 170 ordinary shares under a pre-arranged 10b5-1 plan.

Medtronic's EVP of Global Operations and Supply Chain, Gregory L. Smith, sold 30,000 ordinary shares for approximately $3.06 million.

Medtronic's EVP & President of Cardiovascular, Harry Skip Kiil, sold 8,605 ordinary shares for approximately $787,900 under a pre-arranged trading plan.

Medtronic plc Director William R. Jellison acquired 5,000 ordinary shares for approximately $462,750 in open market transactions.

Medtronic EVP Michael Marinaro disposed of 1,052 ordinary shares to cover tax obligations related to restricted stock unit vesting.

Medtronic's SVP, Chief HR Officer, Matthew R. Walter, reported the vesting of performance share units and exercise of stock options, alongside shares withheld for tax obligations.

Medtronic EVP Brett Wall reported the vesting of performance-based equity awards and subsequent share disposals for tax obligations.

Medtronic's EVP of Global Operations and Supply Chain, Gregory L. Smith, reported the vesting of performance-based equity awards and subsequent share disposals for tax obligations.

Medtronic plc's Chairman and CEO, Geoffrey Martha, reported multiple transactions involving company ordinary shares and derivative securities on August 1, 2025.

Medtronic plc EVP Michael Marinaro reported routine transactions involving the acquisition and disposal of company ordinary shares, primarily related to RSU vesting and tax withholdings.

Medtronic's EVP and President of Cardiovascular, Harry Skip Kiil, acquired 10,457 ordinary shares through RSU vesting and subsequently sold 7,555 shares for tax obligations.

Medtronic's Chief Accounting Officer, Denise L. Blomquist, reported the acquisition of ordinary shares through RSU settlements and stock option exercises, alongside tax-related dispositions.

Medtronic plc's EVP of Global Operations and Supply Chain, Gregory L. Smith, reported a pre-planned transaction involving the withholding of 1,630 ordinary shares for tax purposes related to restricted stock unit vesting.

Medtronic plc's Senior Vice President and Chief HR Officer, Matthew R. Walter, was granted significant equity awards including restricted stock units, performance share units, and stock options, effective July 28, 2025.

Medtronic plc's EVP and President of Neuroscience, Brett A. Wall, was granted restricted stock units, performance share units, and stock options as part of a pre-planned equity compensation package.

Medtronic plc's EVP of Global Operations and Supply Chain, Gregory L. Smith, was granted restricted stock units, performance share units, and stock options, increasing his beneficial ownership.

Medtronic plc's EVP, General Counsel, and Secretary, Michelle Quinn, was granted a substantial package of restricted stock units, performance share units, and stock options, aligning her compensation with future company performance.

Medtronic plc's Executive Vice President and Chief Financial Officer, Thierry Pieton, reported the acquisition of restricted stock units, performance share units, and stock options as part of his compensation.

Medtronic plc's Chairman and CEO, Geoffrey Martha, acquired substantial equity awards, including restricted stock units, performance share units, and stock options, signaling a significant increase in his beneficial ownership.

Medtronic plc's EVP and President of MedSurg and Americas, Michael Marinaro, was granted restricted stock units, performance share units, and stock options effective July 28, 2025, as part of his compensation.

Medtronic plc's EVP and President of Cardiovascular, Harry Skip Kiil, was granted a significant equity compensation package including restricted stock units, performance share units, and stock options.

Medtronic's Chief Accounting Officer, Denise L. Blomquist, received grants of restricted stock units, performance share units, and stock options effective July 28, 2025, aligning her interests with long-term company performance.

Medtronic plc's Chief Accounting Officer, Denise L. Blomquist, reported the disposition of 310 ordinary shares via a gift on June 3, 2025, as per a recent SEC Form 4 filing.